The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.

OBJECTIVE The present study was proposed to examine the matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and vascular endothelial growth factor (VEGF) in patients with metabolic syndrome (MetS), and to compare these parameters with healthy controls. We also compared the possible association of the circulating levels of MMP-2, MMP-9, TIMP-1, TIMP-2, and VEGF with cardiovascular risk factors in patients with MetS. We also compared the possible association of the circulating levels of MMP-2, MMP-9, TIMP-1, TIMP-2, and VEGF with cardiovascular risk factors in patients with MetS. PATIENTS AND METHODS A total of 45 patients with MetS and 17 healthy controls with a body mass index (BMI) less than 25 kg/m2 were enrolled in the study. Plasma MMP-2, MMP-9, TIMP-1, TIMP-2, and VEGF levels were determined using ELISA. RESULTS TIMP-1,-2, MMP-2,-9 levels were significantly higher in patients with MetS compared with healthy controls (p < 0.001). Carotid intima-media thickness and serum VEGF levels were found to be significantly increased (p < 0.01, p < 0.05 respectively) in MetS compared with healthy controls. According to the ROC curves, TIMP-1 levels were both sensitive (93.3%) and specific (81.2%). CONCLUSIONS We observed that the patients with MetS have increased circulating concentrations of MMP-9, MMP-2, and TIMP-1, TIMP-2 that are associated with increased concentrations of VEGF. These findings suggest that MMP-2 may have a role in the increased cardiovascular risk of MetS patients.

[1]  Serag Esmat,et al.  Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship? , 2015, Digestion.

[2]  R. Zheng,et al.  Association between metabolic syndrome and vascular endothelium dysfunction in children and adolescents. , 2014, Genetics and molecular research : GMR.

[3]  B. Duncan,et al.  Early Change of Extracellular Matrix and Diastolic Parameters in Metabolic Syndrome , 2013, Arquivos brasileiros de cardiologia.

[4]  M. Aydın,et al.  The impact of metabolic syndrome on carotid intima media thickness. , 2013, European review for medical and pharmacological sciences.

[5]  D. Noto,et al.  Gelatinases and Their Tissue Inhibitors in a Group of Subjects With Metabolic Syndrome , 2013, Journal of Investigative Medicine.

[6]  M. Moroi,et al.  Disruption of components of vascular endothelial growth factor angiogenic signalling system in metabolic syndrome , 2013, Thrombosis and Haemostasis.

[7]  G. Berg,et al.  Metalloproteinases in metabolic syndrome. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[8]  W. Saxinger,et al.  An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo , 2011, Peptides.

[9]  J. Mosiewicz,et al.  Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome , 2011, Archives of medical science : AMS.

[10]  Joel G. Anderson,et al.  The Metabolic Syndrome and Mind-Body Therapies: A Systematic Review , 2011, Journal of nutrition and metabolism.

[11]  A. Lewiński,et al.  Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia , 2011, Archives of medical science : AMS.

[12]  E. Kowalczyk,et al.  [Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications]. , 2011, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[13]  J. Tanus-Santos,et al.  Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[14]  G. Berg,et al.  Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. , 2008, Metabolism: clinical and experimental.

[15]  J. Nör,et al.  Vascular endothelial growth factor and its relationship with the dental pulp. , 2007, Journal of endodontics.

[16]  A. D'Angelo,et al.  Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. , 2007, Diabetes & metabolism.

[17]  N. Vaziri,et al.  Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. , 2006, Journal of applied physiology.

[18]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[19]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[20]  Kyoung Eun Song,et al.  Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. , 2005, Diabetes research and clinical practice.

[21]  M. Bond,et al.  Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. , 2004, Journal of the American College of Cardiology.

[22]  A. Aljada,et al.  Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. , 2003, Diabetes care.

[23]  P. Wingfield,et al.  TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.

[24]  E. Tsilibary.  Microvascular basement membranes in diabetes mellitus , 2003, The Journal of pathology.

[25]  D. Yue,et al.  High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. , 2003, Atherosclerosis.

[26]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  J. Keiser,et al.  Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. , 1998, Circulation research.

[28]  J. Jesty,et al.  Vascular endothelial groth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatininase a activation and cell proliferation , 1998, International journal of cancer.

[29]  A. Strongin,et al.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.

[30]  P Pignoli,et al.  Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.

[31]  Marie Clark.  What is diabetes? , 1982, British medical journal.

[32]  S. Tyagi,et al.  The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes : the matrix preloaded , 2015 .

[33]  Marco Manca,et al.  Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. , 2007, Endothelium : journal of endothelial cell research.

[34]  R. Kawamoto,et al.  Carotid atherosclerosis in normal-weight metabolic syndrome. , 2007, Internal medicine.

[35]  D. Moller,et al.  Metabolic syndrome: a clinical and molecular perspective. , 2005, Annual review of medicine.

[36]  W. Koenig,et al.  Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. , 2003, Arteriosclerosis, thrombosis, and vascular biology.